NASDAQ NMS - GLOBAL MARKET · EOCN
-6.55% · -$0.2000 · Vol Not reported
Market closed · last close 4:00 PM ET · price as of 15:59:04 ET
Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd

Biotechnology
$2.85
Card
Relationship Map

Follow $EOCN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $EOCN by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Valuation absence reason unknown · Sentiment absence reason unknown
EOCN
Galmed Pharmaceuticals Ltd
Fri Oct 16 · market closed · Markets closed · resumes Mon 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

30/ 100
Veridion Score
Lower range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →or $250/yr
Cancel anytime · or Reserve · $79/moor $790/yr
Confidence: LOW · 4 of 6 factors measured · Fri Oct 16 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
AI Analysis
Sovereign

Why is EOCN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Galmed Pharmaceuticals Ltd
Biotechnology
Listed since
2014
Employees
6
Country
IL

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.91
Day high
$3.09
Day low
$2.33
Previous close
$3.05
52W high
$11.76
-75.76% from high
52W low
$2.33
6% of range
Market cap
$3.3M
EPS
$-12.1298
Beta
0.54
Shares out
1.1M
Avg volume
25.7K
VWAP
$3.05
Last session
Price history computed in-house
1W
-19.49%
1M
-18.10%
3M
-34.74%
1Y
-74.00%
YTD
-52.53%
SMA 50 $3.85 · below
SMA 200 $4.76 · below
52W position 6%

EOCN overview

Veridion Score
30
Registered · 2026-10-16
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around EOCN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Public disclosures

Congress activity in EOCN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

EOCN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EOCN in this window.
Lobbying spend

EOCN lobbying filings, year to date.

Registered lobbying filings matched to Galmed Pharmaceuticals Ltd.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EOCN in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for EOCN.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.